Evaxion A/S (EVAX) Competitors

$4.44 +0.37 (+9.12%)

As of 01:16 PM Eastern

EVAX vs. CNTB, KLRS, IMUX, IPHA, and EQ

Should you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Connect Biopharma (CNTB), Kalaris Therapeutics (KLRS), Immunic (IMUX), Innate Pharma (IPHA), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry.

How does Evaxion A/S compare to Connect Biopharma?

Evaxion A/S (NASDAQ:EVAX) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Evaxion A/S currently has a consensus price target of $11.00, suggesting a potential upside of 147.69%. Connect Biopharma has a consensus price target of $8.67, suggesting a potential upside of 266.46%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Connect Biopharma is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Evaxion A/S has higher revenue and earnings than Connect Biopharma. Evaxion A/S is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.92	-$7.71M	-$1.32	N/A
Connect Biopharma	$60K	2,227.83	-$55.48M	-$1.00	N/A

Evaxion A/S's return on equity of -61.43% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-29.14%
Connect Biopharma	N/A	-88.21%	-74.26%

Evaxion A/S has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.21, suggesting that its stock price is 121% less volatile than the S&P 500.

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by company insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Evaxion A/S had 4 more articles in the media than Connect Biopharma. MarketBeat recorded 5 mentions for Evaxion A/S and 1 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 1.36 beat Evaxion A/S's score of -0.60 indicating that Connect Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Connect Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Evaxion A/S and Connect Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Evaxion A/S compare to Kalaris Therapeutics?

Evaxion A/S (NASDAQ:EVAX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

In the previous week, Evaxion A/S had 4 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 5 mentions for Evaxion A/S and 1 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 1.93 beat Evaxion A/S's score of -0.60 indicating that Kalaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Kalaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 68.1% of Kalaris Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500.

Evaxion A/S has higher revenue and earnings than Kalaris Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Kalaris Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.92	-$7.71M	-$1.32	N/A
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$4.21	N/A

Evaxion A/S's return on equity of -61.43% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-29.14%
Kalaris Therapeutics	N/A	-73.11%	-43.56%

Evaxion A/S currently has a consensus price target of $11.00, suggesting a potential upside of 147.69%. Kalaris Therapeutics has a consensus price target of $14.00, suggesting a potential upside of 174.51%. Given Kalaris Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kalaris Therapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Evaxion A/S beats Kalaris Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Evaxion A/S compare to Immunic?

Immunic (NASDAQ:IMUX) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

Evaxion A/S has higher revenue and earnings than Immunic. Evaxion A/S is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$7.00	N/A
Evaxion A/S	$7.53M	4.92	-$7.71M	-$1.32	N/A

51.8% of Immunic shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 14.0% of Immunic shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Evaxion A/S's return on equity of -61.43% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-1,197.81%	-264.95%
Evaxion A/S	N/A	-61.43%	-29.14%

Immunic presently has a consensus price target of $52.43, indicating a potential upside of 346.73%. Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 147.69%. Given Immunic's stronger consensus rating and higher probable upside, research analysts clearly believe Immunic is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Immunic had 8 more articles in the media than Evaxion A/S. MarketBeat recorded 13 mentions for Immunic and 5 mentions for Evaxion A/S. Immunic's average media sentiment score of -0.07 beat Evaxion A/S's score of -0.60 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Immunic has a beta of 1.2, suggesting that its stock price is 20% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

Summary

Immunic beats Evaxion A/S on 9 of the 15 factors compared between the two stocks.

How does Evaxion A/S compare to Innate Pharma?

Innate Pharma (NASDAQ:IPHA) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

In the previous week, Evaxion A/S had 2 more articles in the media than Innate Pharma. MarketBeat recorded 5 mentions for Evaxion A/S and 3 mentions for Innate Pharma. Innate Pharma's average media sentiment score of 0.20 beat Evaxion A/S's score of -0.60 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Innate Pharma presently has a consensus price target of $5.00, indicating a potential upside of 253.36%. Evaxion A/S has a consensus price target of $11.00, indicating a potential upside of 147.69%. Given Innate Pharma's higher probable upside, research analysts clearly believe Innate Pharma is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Evaxion A/S has lower revenue, but higher earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$10.19M	13.04	-$55.64M	N/A	N/A
Evaxion A/S	$7.53M	4.92	-$7.71M	-$1.32	N/A

Innate Pharma has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500.

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Innate Pharma's return on equity of 0.00% beat Evaxion A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Evaxion A/S	N/A	-61.43%	-29.14%

Summary

Innate Pharma and Evaxion A/S tied by winning 7 of the 14 factors compared between the two stocks.

How does Evaxion A/S compare to Equillium?

Evaxion A/S (NASDAQ:EVAX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Evaxion A/S has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Comparatively, Equillium has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500.

Evaxion A/S presently has a consensus price target of $11.00, indicating a potential upside of 147.69%. Equillium has a consensus price target of $7.67, indicating a potential upside of 252.49%. Given Equillium's stronger consensus rating and higher possible upside, analysts plainly believe Equillium is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Evaxion A/S has higher earnings, but lower revenue than Equillium. Equillium is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evaxion A/S	$7.53M	4.92	-$7.71M	-$1.32	N/A
Equillium	$41.10M	3.35	-$22.40M	-$0.50	N/A

11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Evaxion A/S had 1 more articles in the media than Equillium. MarketBeat recorded 5 mentions for Evaxion A/S and 4 mentions for Equillium. Equillium's average media sentiment score of 0.75 beat Evaxion A/S's score of -0.60 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evaxion A/S	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Equillium	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evaxion A/S's return on equity of -61.43% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evaxion A/S	N/A	-61.43%	-29.14%
Equillium	N/A	-119.19%	-93.79%

Summary

Equillium beats Evaxion A/S on 8 of the 15 factors compared between the two stocks.

Get Evaxion A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVAX vs. The Competition

Export

Metric	Evaxion A/S	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$37.04M	$1.48B	$6.19B	$12.25B
Dividend Yield	N/A	N/A	2.78%	5.24%
P/E Ratio	-3.36	61.73	28.68	27.24
Price / Sales	4.92	5.88	534.15	76.05
Price / Cash	N/A	24.05	43.30	53.97
Price / Book	2.18	4.89	9.97	6.81
Net Income	-$7.71M	-$54.60M	$3.54B	$333.00M
7 Day Performance	N/A	N/A	N/A	0.16%
1 Month Performance	9.38%	7.92%	4.50%	7.10%
1 Year Performance	203.97%	1.20%	40.23%	40.26%

Evaxion A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVAX Evaxion A/S	3.3975 of 5 stars	$4.44 +9.1%	$11.00 +147.7%	+177.8%	$37.04M	$7.53M	N/A	60	News Coverage
CNTB Connect Biopharma	3.4244 of 5 stars	$2.40 -2.0%	$8.67 +261.1%	+191.3%	$138.48M	$60K	N/A	110	Positive News
KLRS Kalaris Therapeutics	3.4879 of 5 stars	$5.64 -6.3%	$14.00 +148.2%	N/A	$138.41M	N/A	N/A	110	Positive News High Trading Volume
IMUX Immunic	2.927 of 5 stars	$10.75 +7.7%	$56.43 +424.9%	+20.0%	$135.94M	N/A	N/A	70
IPHA Innate Pharma	3.6093 of 5 stars	$1.40 flat	$5.00 +257.1%	-42.4%	$131.36M	$10.19M	N/A	220	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVAX) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evaxion A/S (EVAX) Competitors

EVAX vs. CNTB, KLRS, IMUX, IPHA, and EQ

How does Evaxion A/S compare to Connect Biopharma?

Summary

How does Evaxion A/S compare to Kalaris Therapeutics?

Summary

How does Evaxion A/S compare to Immunic?

Summary

How does Evaxion A/S compare to Innate Pharma?

Summary

How does Evaxion A/S compare to Equillium?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evaxion A/S (EVAX) Competitors

EVAX vs. CNTB, KLRS, IMUX, IPHA, and EQ

How does Evaxion A/S compare to Connect Biopharma?

Do analysts rate EVAX or CNTB?

Which has higher earnings and valuation, EVAX or CNTB?

Is EVAX or CNTB more profitable?

Which has more risk and volatility, EVAX or CNTB?

Do institutionals and insiders hold more shares of EVAX or CNTB?

Does the media favor EVAX or CNTB?

Summary

How does Evaxion A/S compare to Kalaris Therapeutics?

Does the media favor EVAX or KLRS?

Do institutionals and insiders hold more shares of EVAX or KLRS?

Which has more risk & volatility, EVAX or KLRS?

Which has stronger valuation & earnings, EVAX or KLRS?

Is EVAX or KLRS more profitable?

Do analysts rate EVAX or KLRS?

Summary

How does Evaxion A/S compare to Immunic?

Which has preferable valuation & earnings, IMUX or EVAX?

Do institutionals & insiders believe in IMUX or EVAX?

Is IMUX or EVAX more profitable?

Do analysts prefer IMUX or EVAX?

Does the media prefer IMUX or EVAX?

Which has more volatility & risk, IMUX or EVAX?

Summary

How does Evaxion A/S compare to Innate Pharma?

Does the media prefer IPHA or EVAX?

Do analysts prefer IPHA or EVAX?

Which has preferable valuation & earnings, IPHA or EVAX?

Which has more volatility & risk, IPHA or EVAX?

Do institutionals & insiders believe in IPHA or EVAX?

Is IPHA or EVAX more profitable?

Summary

How does Evaxion A/S compare to Equillium?

Which has more risk & volatility, EVAX or EQ?

Do analysts prefer EVAX or EQ?

Which has better earnings & valuation, EVAX or EQ?

Do institutionals & insiders believe in EVAX or EQ?

Does the media prefer EVAX or EQ?

Is EVAX or EQ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVAX vs. The Competition

Evaxion A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools